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Abstract 
Aims: We aimed to determine serum dipeptidyl peptidase-4 (DPP-4) activity in a group of 
persons with latent autoimmune diabetes in adults (LADA) and to compare it with persons with 
type 1, type 2 diabetes and healthy controls. 
Methods: DPP-4 activity measurement was performed in 67 persons (21 with type 1, 26 type 2 
and 19 with LADA) and 13 healthy age and gender matched controls.  
Results: Persons with LADA showed highest DPP-4 activity among the study groups 
(32.71±3.55 vs 25.37±2.84 vs 18.57±2.54 vs 18.57±2.61 U/L p<0.001). Mean glutamic acid 
autoantibody in persons with LADA was 164.32±86.28 IU/mL. It correlated with DPP-4 activity 
(r=0.484, p=0.013). Furthermore, DPP-4 activity correlated with waist circumference (r=0.279, 
p=0.034) and glycated haemoglobin A1c (r=0.483, p<0.001), as well as with LDL cholesterol 
(r=0.854, p<0.001) and total daily insulin dose (r=0.397, p=0.001).  In the multinomial 
regression analysis DPP-4 activity remained associated with both LADA (prevalence ratio 1.058 
(1.012-1.287), p=0.001) and type 1 diabetes (prevalence ratio 1.506 (1.335-1.765), p<0.001) 
while it did not show an association with type 2 diabetes (prevalence ratio 0.942 (0.713-1.988), 
p=0.564). 
Conclusions: Persons with LADA express higher DPP-4 activity compared to persons with both 
type 1 and type 2 diabetes. The possible patophysiological role of DPP-4 in the LADA 
pathogenesis needs to be further evaluated. 
Key words: latent autoimmune diabetes in adults, type 1 diabetes mellitus, type 2 diabetes 
mellitus, dipeptidy peptidase-4 
 
 
 
 
 
 
1. Introduction 
Diabetes mellitus reflects a group of carbohydrate, protein and fat metabolism disorders 
characterized by hyperglycemia which eventually leads to micro- and macrovascular 
complications development. Although all forms of diabetes are characterized by hyperglycemia, 
the pathogenic mechanisms by which hyperglycemia arises widely differ. American Diabetes 
Association categorized diabetes mellitus mainly as type 1, type 2 diabetes and the others [1]. 
Type 1 diabetes mellitus (T1DM) is an autoimmune (AI) disease in which absolute insulin 
deficiency and consecutive hyperglycemia results from immune-mediated destruction of insulin-
secreting pancreatic islet cells [1, 2]. Although the majority of persons with T1DM experience 
the acute disease onset under the age of 30 years, during the last decades an accumulating body 
of literature led to the recognition that predominant, autoantibody mediated form of T1DM might 
appear at any age [2-4].  
Latent autoimmune diabetes in adults (LADA) represents a form of autoimmune diabetes that 
resembles type 1, but has a later onset and slower progression towards absolute insulin 
dependency. There are controversies regarding this type of the disease and its terminology which 
is why several attempts have been made in order to better characterization and classification [4]. 
Uncertainties concern almost all aspects of this disease, including:nomenclature, diagnostic 
criteria, epidemiology, natural history, pathogenesis along with genetic, metabolic and 
immunological aspects. Clinical phenotype in persons with AI diabetes ranges from diabetic 
ketoacidosis to diabetes that can be controlled with diet alone [5] and the three criteria namely: 
age at diagnosis, autoantibody positivity and need for insulin treatment conventionally used to 
define adult-onset AI diabetes are non specific. Because autoantibodies to tyrosine phosphatase-
like insulinoma-associated protein 2 (IA2) have been reported to be rather infrequent, the 
diagnosis basically relies on identifying glutamic acid decarboxylase autoantibodie (GADA), 
which is the best single marker for screening [6]. Time to insulin treatment is dependent on local 
clinical judgment and not on the disease process [7], finally, as already mentioned, the disease 
might appear at any age which is not possible to establish the correct diagnosis without Ab 
screening that is not routinely performed. Consequentially, there is no clear management strategy 
in terms of LADA therapy and prevention. Even though ~10% of adults with presumed type 2 
diabetes (T2DM) at diagnosis in fact have LADA, so far there are only few studies evaluating 
therapeutic interventions for LADA, using a hypoglycemic or an immunomodulatory agent. An 
ideal therapeutic approach would aim not only toobtaine a good metabolic control, but also to 
protect residual β-cell mass and function. Conversely, even in persons on insulin, glycaemic 
control is suboptimal, suggesting that insulin alone may not be sufficient [8]. 
Dipeptidyl peptidase-4 (DPP-4) inhibitors represent a new class of oral antidiabetic agents that 
have shown the potential to preserve β-cell function in mouse models of type 2 diabetes  [9, 10], 
in persons with T2DM [11], and even in persons with impaired fasting glucose tolerance [12]. 
DPP-4 inhibition reduces insulitis as well, and stimulates β -cell function in a non-obese diabetic 
mouse model of AI diabetes, a classic model of T1DM [13, 14]. There is an increased serum 
DPP-4 activity [15] and expression on terminally differentiated CD4 T-cells [16] in persons with 
T1DM. Recent trials show that one of the DPP-4 inhibitors, sitagliptin, significantly improves 
glycaemic control in adult persons with T1DM [17] as well as in persons with LADA [18]. 
These observations provided a rationale to test the soluble serum DPP-4 activity in LADA, 
T1DM, T2DM and to compare it with healthy controls. 
 
2. Materials and Methods 
2.1 Study design 
This was a single-centre based study undertaken at University Clinic for diabetes, endocrinology 
and metabolic disease Vuk Vrhovac, Zagreb, Croatia. The study population comprised clinic- 
and hospital-based adult persons with diabetes aged >30 years within at least one year from 
diabetes diagnosis coming for their comprehensive annual review screened for ICA, GAD and 
IA2 Abs. Persons were stratified into four groups: healthy controls (CTRL), persons with T1DM, 
T2DM and LADA. Histories and complete physical examination and laboratory tests were 
performed in all subjects in order to exclude diseases other than T1DM or medications that might 
affect insulin sensitivity. T1DM was defined by undetectable meal stimulated C-peptide 
concentrations (C-peptide <0.2 ng/mL) and positive ICA and GAD (or in combination with IA2 
at least from the previous medical record if the measurement was performed in our Clinic 
laboratory, respectively). LADA was defined by meal stimulated C-peptide concentrations >0.2 
ng/mL and positive GAD auto antibodies and further confirmed clinicallybased on the criteria a 
given by The Immunology of Diabetes Society [19]. Type 2 diabetes was defined as ICA, 
GADA and IA-2 autoantybody negative at the time of diagnosis and without any other evident 
cause of IR that characterises other, specific types of diabetes. All of the persons were using 
insulin which was administered by a basal-bolus regimen, including those with T2DM. The meal 
stimulated test is done with mixed meal (324 (324–528) kcal) comprising approximately 20% 
fat, 60% carbohydrate, and 20% protein. Patients receive subcutaneous injections of long-acting 
insulin analogues before going to sleep the previous day as basal, but not subcutaneous injection 
of rapid-acting insulin analogue as a bolus before ingestion of the test meal on the day of the 
study. 
2.2 Study measurements 
Subjects were studied after an overnight fast. Venous blood samples were collected for the 
determination of biochemistry panel, lipid profile status and DPP-4 activity. Basic 
anthropometric measurements: body mass index (BMI), waist circumference and blood pressure 
were performed on all study subjects.  
HbA1c was measured spectrophotometrically by turbidimetric immuno-inhibition (Olympus 
AU600, Beckman-Coulter, USA) and were expressed in DCCT reference units.  
Cholesterol and triglycerides in serum were measured by an enzymatic colorimetric method. ICA 
antibodies were measured by indirect immunofluorescence. Rate of positivity was calculated by 
determining end-point titres of samples that were converted to the units of Juvenile Diabetes 
Foundation (JDF-U) by comparison with a standard curve of log2 JDF units with log2 of end-
point titre of standard sera. The threshold of detection was >5 JDF units. GAD and IA2 Abs were 
detected with an enzyme-linked immunoadsorbent assay (Euroimmun AG, Luebeck, Germany). 
The cut-off limit was 10 U/ml for GAD Abs and 15 U/ml for IA2 Abs. Participants were 
regarded as GAD and/or IA2 positive if antibody titre exceeded the reference range. 
Sera samples were kept at -20°C until the analysis. DPP-4 activity was measured by a 
colorimetric assay procured from Sigma, St. Louis, MO, USA in a microplate reader (Cary 
Eclipse Varian, Agilent Technologies) at 460 nm, 37 °C in a continuous monitoring for 35 min. 
In this assay, DPP4 cleaves H-Gly-Pro-AMC to release a ﬂuorescent product, 7-Amino-4-Methyl 
Coumarin (AMC) which can be measured spectrophotometrically. One unit of activity was 
deﬁned as the amount of enzyme which will hydrolyse the DPP-4 substrate to yield 1.0 μmol of 
AMC per minute at 37 °C.  
The study protocol complies with the Declaration of Helsinki and was approved by the local 
ethics committee. Written informed consent was obtained from all participants. 
 
2.3 Statistical analysis 
According to our previous studies [20] and the expected standard deviation of sera DPP-4 
activity of 2.56 U/L, the sample size was in accordance with 1-β=0.8 at a significance level of 
α=0.05. Baseline data were reported using descriptive statistics. Normality of distribution for 
continuous variables was analysed using Shapiro-Wilk test. Variables that were not normally 
distributed were log-transformed and described with mean and standard deviation (SD). The 
nominal variables were reported with absolute numbers and/or percentages. Differences between 
groups were examined, depending on the nature of the data, using parametric Differences 
between groups were examined, by One way ANOVA test, followed by Bonferroni’s correction 
and χ 2 test for the attributive variables. Correlations between DPP-4 activity and 
anthropometric, biochemical and immunological activity were tested with Pearsons coefficient of 
correlation. The association of DPP-4 activity and type of diabetes was further tested in the 
multinomial regression analysis including all the variableas reaching p value <0.05 in the 
univariate analysis. Level of statistical significance was chosen to 0.05. Statistical analysis was 
performed by statistical package Statistical Package for the Social Sciences (SPSS) ver.17.0 for 
Windows.  
 
3. Results 
The mean age of our study population was 51.1±14.6 years with a mean duration of diabetes 
20.3±11.3 years while the healthy control group was 49.7±5.5 years old. Participants were 
divided into four groups: 21 persons with T1DM, 26 with T2DM, 19 persons with LADA and 13 
age and gender matched healthy controls (CTRL). The gender distribution was similar in-
between groups (61.9% vs 57.7% vs 57.9% vs 53.8% males). Their baseline anthropometric and 
laboratory data as well as difference in-between them are given in Table 1., except for the mean 
DPP-4 activity of the healthy control group of 18.57±2.61 U/L (Figure 1.)  
 
 
Table 1. Patients anthropometric and laboratory data 
Variable Type 1 diabetes 
N=21 
Type 2 diabetes 
N=26 
LADA 
N=19 
p 
Age (years) 41.6±14.9 53.7±12.5 43.4±11.4 0.09 
Diabetes 
duration 
(years) 
17.65±12.4 20.75±13.95 18.0±13.5 0.003 
Waist 
circumerence 
(cm) 
88.3±14.3 99.9±14.1 90.3±16.9 0.03 
Body mass 
index (kg/m2) 
25.9±3.5 28.6±4.5 26.3±4.6 0.07 
Systolic BP 
(mmHg) 
128.2±27.1 133.1±19.6 132.8±27.1 0.76 
Dyastolic BP 
(mmHg) 
76.6±7.8 84.3±15.1 80.8±11.7 0.15 
Disease 
duration 
(years) 
21.1±11.0 20.2±12.8 18.0±8.8 0.83 
HbA1c (%) 7.1±1.3 7.3±1.4 7.5±1.3 0.53 
HbA1c 
(mmol/mol) 
54±9 56±8 58±9 
Total serum 
cholesterol 
(mmol/L) 
4.8±0.9 5.7±1.6 5.5±2.4 0.22 
HDL 
cholesterol 
(mmol/L) 
1.8±0.6 1.4±0.4 1.7±0.5 0.23 
LDL cholesterol 
(mmol/L) 
2.6±0.7 3.2±2.1 3.4±1.1 0.18 
Triglycerides 
(mmol/L) 
1.03±0.52 1.97±2.86 1.27±0.71 0.21 
Total daily 
insulin dose 
(IU/kg) 
0.59±0.13 0.34±0.14 0.51±0.39 <0.001 
DPP-4 activity 
(U/L) 
25.37±2.84 18.57±2.54 32.71±3.55 <0.001 
Legend: BP- blood pressure; HbA1c-glycated haemoglobin A1c; HDL-high density lipoprotein; 
LDL-low density lipoprotein; DPP-4-dipeptidy peptidase-4 
 
Figure 1. Dipeptidyl peptidase-4 activity among groups; 
Legend: CTRL-healthy control: LADA-latent autoimmune diabetes in adults 
 
 
Mean ICA autoantibody titre in the group with T1DM was 117.14±83.99 JDF units while GAD 
titer was 461.33±102.03 IU/mL. Persons with LADA were ICA negative (<5 JDF units) while 
GAD autoantibody titer was 164.32±86.28 IU/mL. GAD autoantibody correlated with DPP-4 
activity (r=0.484, p=0.013) while ICA titer did not (r=0.191, p=0.204). Furthermore, DPP-4 
activity correlated with waist circumference (r=0.279, p=0.034) and HbA1c (r=0.483, p<0.001), 
as well as with LDL cholesterol (r=0.854, p<0.001) and total daily insulin dose (r=0.397, 
p=0.001) (Figure 2. a-e).  
Figure 2. a) Correlations between GAD Ab titer and dipeptidyl peptidase-4 activity 
               b)  Correlations between waist circumference and dipeptidyl peptidase-4 activity 
              c) Correlations between total daily insulin dose and dipeptidyl peptidase-4 activity 
              d) Correlations between glycated haemoglobin A2 and dipeptidyl peptidase-4 activity 
              e) Correlations between low density lipoprotein cholesterol and dipeptidyl peptidase-4 
activity 
 
  
  
  
In the multinomial regression analysis DPP-4 activity remained associated with both LADA 
(prevalence ratio 1.058 (1.012-1.287), p=0.001) and type 1 diabetes (prevalence ratio 1.506 
(1.335-1.765), p<0.001) while it did not show an association with type 2 diabetes (prevalence 
ratio 0.942 (0.713-1.988), p=0.564). 
 
4. Discussion 
This cross-sectional study was designed in order to examine if there is a difference in soluble 
serum DPP-4 activity in persons with different types of diabetes compared to healthy controls 
with special emphasis on persons with LADA. Our study reports several findings: 1) persons 
with LADA express higher DPP-4 activity compared to other types of diabetes; 2) DPP-4 
activity correlates with waist circumference, LDL cholesterol, total daily insulin dose and GAD 
autoantibody status; 3) no significant difference was found between DPP-4 activity in persons 
with T2DM compared to healthy controls. 
DPP-4 is ubiquitously distributed, predominantly found on endothelial and epithelial cells 
throughout the body [21, 22].
 
A fraction of soluble DPP-4 however, originates from the immune 
system cells which explain its altered abundance and the circulating activity in various immune 
mediated conditions [23] including T1DM [24]. Recent data suggest that DPP-4 activity is higher 
in persons with T1DM compared to healthy controls independently of islet-cell antibody status, 
C-peptide concentration, disease duration or HbA1c level
 
[24] and in an inverse correlation with 
body mass index (BMI) and insulin sensitivity [24,25]. This is in accordance with our study 
results because patophysiology of LADA comprises an autoimmune component while its 
phenotype usually resembles T2DM. However, we also showed that DPP-4 activity correlates 
with GAD autoantibody titre which might confirm its meaning in the pathophysiological 
background of the disease. This is partially in accordance with the study of Iwbuchi et al. (2013) 
[25] as well as with Varga et al. (2010) who demonstrated a significantly higher DPP-4 activity 
in the AI form of diabetes,a strong correlation with anthropometric parameters and glycaemic 
control [24]. We could explain this with the fact that AI diabetes is a T-cell mediated organ-
specific disease, initiated by the imbalance between pathogenic and regulatory T-lymphocytes. 
DPP-4 is the lymphocyte cell surface protein CD26, critical in T-cell biology as a marker of T-
cell activation [24,26]. DPP-4 inhibition increased regulatory T-cells and reversed recent-onset 
diabetes in a non-obese mouse model of AI diabetes [27]. Those results suggest that the DPP4 
activity might be an important factor in determination of diabetes type . 
Our third finding is partially in accordance with the study of Firneisz et al. [26] (2010) who 
determined serum DPP4 activity at fasting sate and after test meal in 41 persons with T1DM, 87 
with T2DM accompanied with prominent insulin resistance (IR) and in 25 healthy volunteers. 
Serum DPP-4 activity was significantly higher in both fasting and postprandial state in persons 
with T1DM than in T2DM compared to control subjects irrespective of HbA1c or fasting serum 
glucose. In our study, persons with LADA had significantly higher waist circumference than 
persons with T1DM and required higher insulin dose than persons with T2DM which could 
mean that they also had higher degree of IR. 
Existing studies indicate that DPP-4 inhibitors have the potential to protect β-cell function [11, 
12] in persons with T2DM as well as in a mouse model of AI diabetes [15] which indicates the 
possible role of DPP-4 activity in the disease pathogenesis . Our present results are consistent 
with that hypothesis especially because LADA might represent the combination of underlying 
risk factors of both types of diabetes.  
Because most subjects in our study had similar diabetes duration, we conclude that DPP-4 
activity reflects the joint contribution of IR characteristics and β-cell function in persons with 
LADA. Recently  Johasen et al [28] found that another DPP-4 inhibitor, linagliptin, preserves β-
cell function in persons with LADA during a 2-year study. However, the beneficial metabolic 
effect of DPP-4 inhibitors in addition  to insulin therapycould occur independently of immune 
effects leading secondary to reduced β-cell stress, reduced glucagon, or β-cell regeneration. 
Finally, because persons with LADA showed the worse glycaemic control in-between groups, it 
might be evident that insulin alone is inadequate in the LADA treatment  
Small sample size and the cross-sectional design of the study puts the limitation of generating 
any general conclusions from our study. The autoantibody status was not determined at diagnosis 
and IR was not accessed. Furthermore, DPP-IV is a membranous enzyme expressed in 
endothelial cells, epithelial cells, and T cells, however, we do not know to what extent the 
soluble DPP-4 represents the DPP-4 activity in whole body. Thus, the small increase of DPP-4 
activity in the samples from LADA patients is difficult to interpret its significance. 
In conclusion, we concider increased DPP-4 activity in LADA compared to other diabetes types 
a reflection of combined autoimmunity and IR. A number of attractive therapeutic interventions 
may be envisioned for prevention of β-cell deterioration and progression towards insulin 
dependency. Those include hypoglycemic and immunomodulatory agents, a possibly a 
combination of those if provided that they are safe. Because the AI process in LADA is thought 
to be slower than in T1DM, there is a larger window of opportunities for intervention. DPP-4 
inhibitors might represent an appropriate therapeutic approach that offers metabolic control and 
at the same time might improve the natural history of the disease (i.e., maintains/increases the 
residual β-cell mass and/or function) which needs to be evaluated in further prospective and 
interventional studies using DPP-4 inhibitors in persons with LADA. 
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